FUNDAMENTALS |
MarketCap: |
0.178 mill
|
EPS: |
-0.0400
|
P/E: |
-0.0100
|
Earnings Date: |
N/A |
SharesOutstanding: |
592.20 mill
|
Avg Daily Volume: |
0.0001 mill
|
RATING
2024-04-23 |
B-
|
Sell
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
2/15 | 3/15 | 4/15 | 1/16 | 2/16 | 3/16 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0100 | sector: PE 29.05
|
PE RATIO: COMPANY / INDUSTRY |
0.00x
|
Company: PE -0.0100 | industry: PE 136.10
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0003 - 0.0003
( +/- 0.00%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2016-08-15 | Belldegrun Arie | Buy | 714 285 | Common Stock |
2016-08-15 | Belldegrun Arie | Buy | 357 142 | 2016 Series F Warrants (right to buy) |
INSIDER POWER |
0.00
|
Last
89 transactions |
Buy:
17 291 951 | Sell:
681 614 |
Forecast:
01:40 - $0.0020
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0003 (0.00% )
|
Volume |
0.0035 mill
|
Avg. Vol. |
0.0001 mill
|
% of Avg. Vol |
5 737.70 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ARNI
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.